BRAF and melanoma: Considering that Her2-overexpressing SKBR3 cells and V600E-BRAF-mutant A375 melanoma cells respond to sub-toxic DSF and H2O2 generators, it may be wortwhile to further investigate pre-clinically whether DSF cooperates to perturb redox homeostasis and attenuate resistance to targeted therapy with trastuzumab in Her2-overexpressing breast cancer [57] or with vemurafenib in V600E-mutant BRAF melanoma cells [58].